-
2 months ago | 
jacc.org | Harlan M. Krumholz |Biykem Bozkurt |Y. Chandrashekhar |Bonnie Ky
JACC Journals › JACC › Archives › Just Accepted JACC. . Epublished DOI: 10.1016/j.jacc.2025.02.006FiguresReferencesRelatedDetails InformationCopyright © 2025, American College of Cardiology Foundation. Published by Elsevier Article History ReceivedFebruary 3, 2025AcceptedFebruary 3, 2025Published onlineFebruary 12, 2025
-
Dec 6, 2024 | 
digitalcommons.library.tmc.edu | Paul Douglass |Dipti Itchhaporia |Biykem Bozkurt |Robert Roswell
Keywords American College of Cardiology (ACC), cardiovascular disparities, community engagement and partnerships, health equity, health equity education, health equity frameworks, innovative health care technology, racial and ethnic health disparities, social determinants of health (SDOH), workforce diversity in cardiology Abstract Advancements in cardiovascular (CV) disease management are notable, yet health inequities prevail, associated with increased morbidity and mortality noted among...
-
Dec 5, 2024 | 
digitalcommons.library.tmc.edu | Biykem Bozkurt |Ajith Nair |Arunima Misra |Claire Scott
Keywordsneprilysin, neprilysin inhibitor, NEP inhibitor, angiotensin receptor–neprilysin inhibitor, ARNi, heart failure, sacubitril, sacubitril/valsartanAbstractThis article provides a contemporary review and a new perspective on the role of neprilysin inhibition in heart failure (HF) in the context of recent clinical trials and addresses potential mechanisms and unanswered questions in certain HF patient populations.
-
Dec 5, 2024 | 
digitalcommons.library.tmc.edu | Aliza Hussain |Arunima Misra |Biykem Bozkurt
AbstractHeart failure (HF) is a major health problem worldwide. The development of effective drug and/or device therapy is crucial to mitigate the significant morbidity, mortality and healthcare costs associated with HF. The choice of endpoint in clinical trials has important practical and clinical implications. Outcomes of interest including mortality and HF hospitalisations provide robust evidence for regulatory approval granted there is sufficiency of safety data.
-
Aug 14, 2024 | 
radcliffecardiology.com | Biykem Bozkurt |Muthiah Vaduganathan |Pardeep S. Jhund
Faculty: Overview Join us for an unparalleled educational journey dedicated to tackling the complexities of managing HFpEF and HFmrEF patients. This CME-accredited live roundtable is chaired by Dr Biykem Bozkurt (Baylor College of Medicine, US) and features insights from renowned experts Prof Pardeep Jhund (University of Glasgow, UK) and Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, US).
-
Jul 1, 2024 | 
jacc.org | Paul Douglass |Dipti Itchhaporia |Biykem Bozkurt |Robert Roswell
IntroductionSince its inception nearly 75 years ago, the American College of Cardiology (ACC) has been steadfast in understanding the needs of the members in the organization by providing updated clinical and educational practices, promoting policies and initiatives focused on improving cardiovascular (CV) health for all. These inclusive efforts were perhaps evident as early as 1951, when ACC inducted the first Black cardiologist Dr John Beauregard Johnson.
-
Jul 1, 2024 | 
jacc.org | Biykem Bozkurt
References1. "2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol . 2022;79:17: e263-e421. 2. "A randomized, controlled trial of 3.0 mg of liraglutide in weight management". N Engl J Med . 2015;373:1: 11-22. 3. "Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure". J Am Coll Cardiol .
-
Mar 26, 2024 | 
nature.com | Biykem Bozkurt
AbstractThe prevention and treatment strategies for heart failure (HF) have evolved in the past two decades. The stages of HF have been redefined, with recognition of the pre-HF state, which encompasses asymptomatic patients who have developed either structural or functional cardiac abnormalities or have elevated plasma levels of natriuretic peptides or cardiac troponin.
-
Feb 1, 2024 | 
jacc.org | Biykem Bozkurt
References1. "It Is Time to screen for heart failure: why and how?"J Am Coll Cardiol HF . 2022;10:598-600. 2. "2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol . 2022;79:e263-e421. 3. "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes". N Engl J Med . 2015;373:2117-2128. 4.
-
Jan 1, 2024 | 
jacc.org | Anuradha Lala |Carine Hamo |Biykem Bozkurt |Mona Fiuzat
References1. "Pathophysiology and therapeutic approaches to acute decompensated heart failure". Circ Res . 2021;128:1468-1486. https://doi.org/10.1161/circresaha.121.318186. 2. "Effect of nesiritide in patients with acute decompensated heart failure". N Engl J Med . 2011;365:32-43. https://doi.org/10.1056/NEJMoa1100171. 3.
